Eos

Dxcover is a clinical-stage liquid biopsy firm that is developing diagnostics for the early diagnosis of numerous malignancies, when treatment has a better possibility of having an influence on outcomes. The business was the first to use infrared spectroscopy of circulating pan-omic indicators to detect and identify cancer. The business has generated compelling clinical data on the diagnosis of Stage I and Stage II malignancies with high accuracy. Dxcover was established in 2016 in Glasgow, Glasgow City by David S Palmer, Holly Butler, and Matthew Baker.

Penrhos Bio creates novel, organically inspired substances to reduce microbial biofilms. Its platform offers a sustainable, low-toxicity alternative to existing biocides using molecules to provide marine, textile, paper, household cleaning, and medical industries with resolutions to microbial contamination problems.

Carcinotech is revolutionising cancer research by manufacturing 3D-printed micro-tumours using patient-derived biopsies, primary cells, immune cells, and cancer stem cells. Our advanced offering provides a platform for rapid, ethical, and accurate drug screening, pre-clinical, and personalised medicine testing. Carcinotech’s goal is to accelerate drug screening and enable the delivery of more effective cancer treatments to market. Using patient biopsies, tissue engineering, advanced robotic manufacturing, and quality control to produce highly predictive, assay-ready printed tumours at significant throughput. This provides our clients with a “clinical biopsy” quality model, using isolated patient-specific cells and representing donor-specific cancer heterogeneity. Our vision is to be at the forefront of cancer drug testing and provide personalised medicine testing to each individual suffering from cancer to better their chance of treatment and survival. Working with global partners, leading pharma companies, surgeons, pathologists, and clinicians Carcinotech is changing the face of oncology drug development by working to make this vision a reality.

Cumulus Oncology Limited develops oncology drugs. It provides nodus oncology and modulus oncology services. The company was incorporated in 2017 and is based in Edinburgh, United Kingdom.

Wobble Genomics specializes in maximizing RNA and DNA sequencing efficiency for the discovery and detection of nucleic acid biomarkers.

Dxcover is a clinical-stage liquid biopsy firm that is developing diagnostics for the early diagnosis of numerous malignancies, when treatment has a better possibility of having an influence on outcomes. The business was the first to use infrared spectroscopy of circulating pan-omic indicators to detect and identify cancer. The business has generated compelling clinical data on the diagnosis of Stage I and Stage II malignancies with high accuracy. Dxcover was established in 2016 in Glasgow, Glasgow City by David S Palmer, Holly Butler, and Matthew Baker.

RAB-Microfluidics diagnose early signs of failure in rotating equipment such as gearboxes in wind turbines, generators in shipping vessels, engines in mining industry and prevent equipment failure using our patented microfluidic technology and AI capabilities. RAB-Microfluidics have automated the lubricating oil analysis process using microfluidic technology to provide in real-time the data driven information required to identify deterioration of equipment and incipient failure to revolutionise maintenance practices. We are advancing the evolution of maintenance strategies to secure equipment reliability, increase equipment effectiveness and availability through early diagnosis of machine failure across many industries, such as maritime, renewable wind, aerospace and defence, processing, and manufacturing amongst others. Our mission is to provide intelligent insights on machinery condition through data driven automation and digitisation solutions to achieve our vision of effectively transitioning businesses Condition-based Maintenance (CbM) and Predictive Maintenance (PdM) strategies.

Dxcover is a clinical-stage liquid biopsy firm that is developing diagnostics for the early diagnosis of numerous malignancies, when treatment has a better possibility of having an influence on outcomes. The business was the first to use infrared spectroscopy of circulating pan-omic indicators to detect and identify cancer. The business has generated compelling clinical data on the diagnosis of Stage I and Stage II malignancies with high accuracy. Dxcover was established in 2016 in Glasgow, Glasgow City by David S Palmer, Holly Butler, and Matthew Baker.

GM Flow offer a range of flow measurement services and products, to the oil and gas industry.

Rooser connects seafood buyers and suppliers across Europe, providing them with the tools they need to trade efficiently, negotiate prices, and process deliveries. Rooser is located in Edinburgh, Scotland.